The FDA issued its expected guidance on rare disease drug development in late August, 2015, and public responses are due in October.  Behind the scenes is the buzz of collaboration between patient advocacy groups and drug developers as we analyze, exchange thoughts, and prepare our responses to this important document. (Geeks Talk Clinical)